Lectures and seminars OnkPat Friday Seminar - Clinical and translational analyses in the neoadjuvant PREDIX trials in breast cancer: Biological insights and clinical implications

Bio

Theodoros Foukakis, MD PhD is Professor of Oncology at Karolinska Institutet, and senior attending physician and scientific head for breast cancer at the Comprehensive Cancer Centre, Karolinska University Hospital, Stockholm, Sweden. He is head of the national guidelines group for breast cancer in Sweden, member of the Swedish Breast Cancer Group (SweBCG), and Steering Committee Member of The Early Breast Cancer Trialists' Collaborative Group (EBCTCG).

Dr. Foukakis completed his medical studies at the University of Crete, Greece in 2002 and moved to Stockholm, Sweden where he pursued a PhD in Cancer Genetics at Karolinska Institutet. Subsequently he had a clinical training in Oncology at Karolinska University Hospital between 2005-2009 and has since then worked as a specialist, combining clinical work with research, focusing on breast cancer.

He has led several investigator-initiated trials sponsored by Karolinska University Hospital and served as national principal investigator for many industry sponsored trials from phase 1 to phase 3.

He is leading a research group of 22 members and has independent funding obtained in national or international competition over the last 10 years. His group is particularly interested in drug and biomarker development in breast cancer with focus in multi-omics analyses and machine-learning.

Selected publications

Prognostic significance of tumour Ki-67 dynamics during neoadjuvant treatment in patients with breast cancer: a population-based cohort study.
Toli MA, Liu X, Massa D, Lando S, Boman C, Tsiknakis N, Tranchell C, Papakonstantinou A, Fotia G, Vernieri C, Guarneri V, Bergh J, Dieci MV, Bergman LE, Matikas A, Foukakis T
Lancet Reg Health Eur 2025 Nov;58():101432

Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial.
Zerdes I, Matikas A, Mezheyeuski A, Manikis G, Acs B, Johansson H, Boyaci C, Boman C, Poncet C, Ignatiadis M, Bai Y, Rimm DL, Cameron D, Bonnefoi H, Bergh J, MacGrogan G, Foukakis T
NPJ Breast Cancer 2025 Mar;11(1):23

Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer.
Wang K, Zerdes I, Johansson HJ, Sarhan D, Sun Y, Kanellis DC, Sifakis EG, Mezheyeuski A, Liu X, Loman N, Hedenfalk I, Bergh J, Bartek J, Hatschek T, Lehtiö J, Matikas A, Foukakis T
Nat Commun 2024 May;15(1):3837

Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial.
Matikas A, Johansson H, Grybäck P, Bjöhle J, Acs B, Boyaci C, Lekberg T, Fredholm H, Elinder E, Margolin S, Isaksson-Friman E, Bosch A, Lindman H, Adra J, Andersson A, Agartz S, Hellström M, Zerdes I, Hartman J, Bergh J, Hatschek T, Foukakis T
Clin Cancer Res 2023 Feb;29(3):532-540

Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial.
Hatschek T, Foukakis T, Bjöhle J, Lekberg T, Fredholm H, Elinder E, Bosch A, Pekar G, Lindman H, Schiza A, Einbeigi Z, Adra J, Andersson A, Carlsson L, Dreifaldt AC, Isaksson-Friman E, Agartz S, Azavedo E, Grybäck P, Hellström M, Johansson H, Maes C, Zerdes I, Hartman J, Brandberg Y, Bergh J
JAMA Oncol 2021 Sep;7(9):1360-1367

Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing.
Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T, Crosetto N, Foukakis T, Navin NE
Cell 2018 May;173(4):879-893.e13